Göğüs Hastalıkları
Synopsis
This text covers lower respiratory tract infections, focusing on acute bronchitis, chronic bronchitis, pneumonia, and pneumococcal vaccination. Acute bronchitis is an inflammatory disease of the tracheobronchial tree mainly caused by viral pathogens; it is self-limiting and generally does not require antibiotics. Chronic bronchitis is defined by cough and sputum production for at least three months per year over two consecutive years, with smoking being a major risk factor and cessation of irritants as the primary goal. Pneumonia is an infection and inflammation of the lung parenchyma, presenting with symptoms such as dyspnea, cough, fever, and rusty sputum. Diagnosis relies on physical examination and radiological evidence of pulmonary infiltrates. Risk scores including CURB-65, PSI, SMART-COP, and A-DROP guide hospitalization decisions, where a CURB-65 score of 2 or more indicates hospital admission. Major criteria for intensive care admission include invasive mechanical ventilation and septic shock. Prompt administration of antibiotics within 4–8 hours is essential for prognosis. For primary prevention, conjugate (PCV13) and polysaccharide (PPSV23) pneumococcal vaccines are recommended for adults aged 65 and older as well as other high-risk groups with chronic diseases.
References
Wenzel RP, Fowler AA III. Clinical practice. Acute bronchitis. N Eng J Med 2006;355:2125.
Wark P. Bronchitis (Acute). BMJ Clin Evid. 2015; 2015: 1508.
Clark TW, Medina MJ, Batham S, et al. Adults hospitalised with acute respiratory illness rarely have detectable bacteria in the absence of COPD or pneumonia; viral infection predominates in a large prospective UK sample. J Infect. 2014;69(5):507–515.
Braman SS. Chronic cough due to acute bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006;129(1 suppl):95S–103S.
Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community acquired pneumonia. Arch Intern Med 1997;157:1453.
Smucny JJ, Becker LA, Glazier RH, et al. Are antibiotics effective treatment for acute bronchitis? A meta-analysis. J Fam Pract. 1998;47(6):453–460.
Evans AT, Husain S, Durairaj L, et al. Azithromycin for acute bronchitis: a randomised, double-blind, controlled trial. Lancet. 2002;359(9318):1648–1654.
Pelkonen M, Notkola IL, et al. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006;130:1129–1137. .
Kim V, Han MK, Vance GB, D, et al. The COP-DGene Investigators. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest 2011;140:626–633. .
American Lung Association. Trends in COPD (chronic bronchitis and emphysema): morbidity and mortality. Washington, DC: Research and Program Services Division, Epidemiology and Statistics Unit, Americal Lung Association; 2011.
Sherman CB, Xu X, Speizer FE, et al. Longitudinal lung function decline in subjects with respiratory symptoms. Am Rev Respir Dis 1992;146:855–859.
Swan GE, Hodgkin JE, Roby T, et al. Reversibility of airways injury over a 12-month period following smoking cessation. Chest 1992;101:607–612.
Trotter CL, Stuart JM, George R, et al. Increasing hospital admissions for pneumonia, England. Emerg Infect Dis 2008; 14: 727–733.
Heron M. Deaths: leading causes for 2015. Natl Vital Stat Rep 2017;66(5):1–76.
Almirall J, Serra-Prat M, Bolíbar I, et al. Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies.Respiration. 2017;94(3):299-311.
Metlay JP, Waterer GW, Long AC, et al. Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019:e45-e67.
Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis.Crit Care. 2012;16(4): R141.
Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-44.
Kobayashi M, Bennett NM, Gierke R, et al. Centers for Disease Control and Prevention. MMWR. Intervals between PCV13 and PPSV23 vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). September 4, 2015;64:944-47.